5Lee JH,Kim SH,Oh SY,et al. Third-line docetaxel chemothera-py for recurrent and metastatic gastric cancer[J]. Korean J In-tern Med,2013,28(3) :314-321.
6Luo H, Yu Z,Gao H,et al. Efficacy and tolerability of docetaxeland cisplatin plus S-l for advanced gastric cancer[J]. J BUON,2013,18(1):154-161.
7Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit withdocetaxel plus fluorouracil and cisplatin compared with cisplatin andfluorouracil in a phase trial of advanced gastric or gastroesophagealcancer adenocarcinoma: the V-325 Study Group [J]. J Clin Oncol,2007,25C22):3205-3209.
8Kanat O,O’Neil BH. Metastatic gastric cancer treatment:a lit-tle slow but worthy progress[J]. Med Oncol,2013.30(1) :464.
9Huang D,Ba Y, Xiong J, et al. A multicentre randomised trialcomparing weekly paclitaxel + S-l with weekly paclitaxel +5-fluorouracil for patients with advanced gastric cancer[J]. Eur JCancer,2013,49(14):2995-3002.
10Van Cutsem E,Moiseyenko VM,Tjulandin S,et al. Phase HI study ofdocetaxel and cisplatin plus fluorouracil compared with cisplatin and flu-orouracil as first-line therapy for advanced gastric cancer:a report of theV325 study group[J], J Clin Oncol,2006,24(31) :4991-4997.
